Christian Valdemar Vinge Leisner

Title: Christian Valdemar Vinge Leisner: Innovator in Cancer Treatment

Introduction

Christian Valdemar Vinge Leisner is a notable inventor based in Thalwil, Switzerland. He has made significant contributions to the field of cancer treatment through his innovative work in antigen binding proteins. With a total of two patents to his name, Leisner is recognized for his advancements in the medical and biotechnological sectors.

Latest Patents

Leisner's latest patents include the development of MAGE-A4 peptide dual T cell engagers. These patents describe antigen binding proteins that specifically target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Additionally, the patents detail multispecific antigen binding proteins that comprise an antigen binding domain with specificity to CD3, along with at least one MAGE-A4 pMHC antigen binding domain. Methods for treating cancer using these innovative proteins are also outlined. Another significant patent focuses on MAGE-A4 peptide-MHC antigen binding proteins, which specifically recognize target MAGE-A4 pMHC. This patent includes methods for producing these antigen binding proteins and nucleic acid libraries encoding them.

Career Highlights

Christian Valdemar Vinge Leisner is currently associated with Cdr-life AG, where he continues to push the boundaries of cancer research and treatment. His work is pivotal in developing new therapeutic strategies that could potentially improve patient outcomes in oncology.

Collaborations

Leisner collaborates with talented individuals in his field, including Anna Maria Sobieraj and Fabian Bert Scheifele. These collaborations enhance the innovative capacity of his research and contribute to the advancement of cancer therapies.

Conclusion

Christian Valdemar Vinge Leisner is a prominent figure in the realm of cancer treatment innovations. His patents and ongoing work at Cdr-life AG reflect his commitment to improving healthcare through scientific advancements.